 Zealand Pharma AS NASDAQ: ZEAL has announced topline results from its second Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism CHI, a condition in which individuals have abnormally high levels of insulin. Dasiglucagon met the trials. 